All News

The adjusted dosing for donanemab in early AD reduced ARIA-E risk by 41% compared to the original dosing, without compromising efficacy.

The Fujirebio in-vitro diagnostic has shown positive and negative predictive values of 92% and 97%, respectively, for early AD detection and will be offered by end of summer.

GLP-1 medications are transforming obesity medicine but strong evidence points to a need for integrating nutrition and lifestyle support for lasting weight loss and health benefits.

Richard Rosenfeld, MD, MPH, MBA, explains how clinical guidelines for diabetes remission from the American College of Lifestyle Medicine differ from and augment existing recommendations.

Your daily dose of the clinical news you may have missed.

Dr Khanna discusses dosing challenges, metabolic issues, and potential complications from medications like acetaminophen.

Discover essential clinical insights on Alzheimer disease screening in primary care, eczema treatments, and the latest in cancer detection and diet impacts on CHD risk.

New findings showcase the transformative impact of long-acting injectable therapies for effective HIV treatment and prevention.

Exercise and strength/balance training are keys to protecting against falls, but careful assessments at each clinic visit may uncover other risks to address.

Caissa Troutman, MD, discusses how clinicians can tailor management plans to reduce risk of developing T2D in patients with obesity.

A new study found racial disparities in COVID-19 antiviral prescribing, with clinic site, test type, and telehealth use explaining up to half the gap for Black and Latino patients.

Among recipients of high-dose CVXGA, relative vaccine effectiveness was 67.8% against symptomatic COVID infection at a median 7.3 months post-vaccination.

ADA 2025: Dapiglutide showed promising safety and weight loss results in a phase 1b trial, targeting obesity and inflammation with once-weekly dosing.

The investigational IL-13 inhibitor showed topline EASI-75 of 66.9% and reduced injection frequency in part A of the APEX phase 2 clinical trial.

Social media support for the Keto diet and raves about the next best dietary supplement worry HCPs; they also feel their own nutrition education is subpar.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

Depression and anxiety affect as many as 1 in 4 people with AD, with pruritus, sleep disorders, education level, and comorbidities identified as independent risk factors.